Dapsone-induced methemoglobinemia
Hope Vertrice Askew, PharmD
PGY-1 Pharmacy Resident
Parkland Health
March 9th, 2022
Objectives
Describe the pathophysiology of dapsone-induced methemoglobinemia
Understand and interpret lab values and imaging associated with methemoglobinemia
Identify common clinical presentations and symptoms associated with methemoglobinemia
Compare the pharmacologic treatment options for methemoglobinemia
Design a treatment plan for a patient with Dapsone-induced methemoglobinemia
2
Our Patient
IP is a 30-year-old Hispanic female, who presented to Parklandās ED on 10/29/21 for anorexia, abdominal pain, and diarrhea x 2 weeks with no relief from OTCās.
3
Patient: IP
HPI: Recently admitted to Parkland one month ago where she was started on PJP prophylaxis due to anticipated chronic steroid dependence (newly diagnosed lupus nephritis). After admission, her SpO2 began to decline rapidly (94% to 84%) now requiring 6L nasal canula with no explained insinuating cause.
Social History:
PMH:
Family History:
4
Medications Prior to Admission
Medication | Dose/Frequency | Notes: |
Acyclovir | 400 mg twice daily | CMV/antiviral prophylaxis |
Amlodipine | 10 mg daily | |
Atorvastatin | 40 mg daily | Chol = 517, LDL = 336, TG = 665 |
Carvedilol | 25 mg twice daily | |
Dapsone | 100 mg daily | PJP prophylaxis |
Ergocalciferol | 50,000 units weekly | |
Lisinopril | 10 mg daily | |
Mycophenolate | 1,000 mg twice daily | lupus nephritis |
Pantoprazole | 20 mg daily | GI prophylaxis due to high dose steroid |
Prednisone | 60 mg daily | No taper planned, f/u renal outpatient |
OTC: acetaminophen, ibuprofen, aspirin - as needed for pain unknown dose or frequency
Allergies: diclofenac - rash
5
Review of Systems and Physical Exam (10/29/21)
6
General | Well-developed and well-nourished No fever or chills |
HEENT* | No headaches or sore throat No vision changes or eye pain Head, ears, eyes, nose, and mouth physical presence normal |
Respiratory | No cough or dyspnea No respiratory distress, breath sounds clear and normal No hemoptysis |
Cardiovascular | Regular rhythm and heart sounds No lower extremity edema |
*HEENT: head, ears, eyes, nose, throat
Review of System and Physical Exam (10/29/21)
Skin | No rash or itching Warm and dry No cyanosis or edema Skin intact with no cuts, bruises, ulcers, or abrasions |
Gastrointestinal | Nausea, vomiting Abdominal pain (no distention) and diarrhea No melena/hematochezia or hematemesis |
Genitourinary | No bleeding |
Neurological | No dizziness or weakness Symmetric facial/extremity movement, normal ambulation A&O x 4 |
Psychiatric/Behavioral | Mood and affect normal |
7
Objective Findings - Upon Admission (10/29/21)
8
Vitals
Labs and Imaging
G6PD deficiency, oxidative stress & toxic metabolite in RBCās are increased
Leads to the iron and bond breaking ā oxidative drug-induced hemolytic anemia
When the RBC passes through the spleen, macrophages take a ābiteā
Bite Cells
8
Objective - Labs (10/29/21 𔪠11/2/21)
9
CBC | BMP | Other | |||
WBC | 7.93 𔪠5.98 | Na | 135 | Iron | 442 (H) |
RBC | 1.87 | K | 4.4 | Pct Sat | 79 (H) |
Hgb | 6.5 (L) 𔪠4.8 | CO2 | 14 (L) | Ferritin | 319 (H) |
Hct | 20.0 (L) | BUN | 103 (H) 𔪠74 (H) | B12 | 462 |
MCV | 107 (H) 𔪠107 | SCr | 2.85 (H) 𔪠2.45 (H) | MetHb | 21.1 (H) |
PLT | 208 𔪠190 | eGFR | 19 (L) | Haptoglobin | <5 |
Neutro ABS | 7.14 (H) | | | Lactate Dehydrogenase | 401 (H) |
Lymph ABS | 0.35 (L) | | | AST | 20 |
EOS Ab | <0.03 (L) | | | ALT | 14 |
Hgb: hemoglobin
MetHb: methemoglobin
DAT: negative (11/4/21); Reticulocyte count: 4.7 (11/2/21)
9
Drug-Induced ļæ½Methemoglobinemia
Pathophysiology and Epidemiology
What is methemoglobinemia?
In normal hemoglobin, iron is in itās ferrous (Fe2+) state 𔪠allows for binding of oxygen (O2) in lungs that can be further released to the tissues
Methemoglobin is a form of hemoglobin that has been altered due to oxidization
Condition where ferrous ironās (Fe2+) heme group becomes oxidized to ferric iron (Fe3+)
Results in functional anemia, due to oxygen unable to effectively be delivered to hypoxic tissues despite the rich O2 environment
Am J Physiol. 1942;137:56
Drug Saf. 1996;14(6):394
Williams Hematology, 10e. McGraw Hill; 2021
11
What is methemoglobinemia?
Oxidation (removing e-) is NOT the same as oxygenation (O2 binding)
Ferric heme of methemoglobin does NOT bind to O2
Consequences depend on if MetHb is chronically or acutely increased
Am J Physiol. 1942;137:56
Drug Saf. 1996;14(6):394
Post TW, ed. UpToDate.
Williams Hematology, 10e. McGraw Hill; 2021
12
Influences other Hgb molecules to have decrease O2 affinity
Results, in the inability of O2 binding 𔪠left-shifts of O2 curve = anemia
What is methemoglobinemia?
Treatment is very specific and usually not available in an EMS setting
Am J Physiol. 1942;137:56
Drug Saf. 1996;14(6):394
Williams Hematology, 10e. McGraw Hill; 2021
13
Quick Reminder: IPās
MetHb = 21
Most common causes for ļæ½drug-induced methemoglobinemia
ācainesā
lidocaine, xylocaine, benzocaine, cocaine
Antimalaria Agents
chloroquine, primaquine, hydroxychloroquine
Nitrates and Nitrites
Sulfa Medications
trimethoprim/sulfamethoxazole, furosemide, dapsone
Am J Physiol. 1942;137:56
Drug Saf. 1996;14(6):394
N Engl J Med. 1968;279(21):1127-1131
Arch Intern Med. 2007;167(18)
Cochrane Database Syst Rev. 2014
Williams Hematology, 10e. McGraw Hill; 2021s
14
How dapsone causes methemoglobinemia
15
Dapsone is metabolized and bioactivated in the liver to a potent metabolite, hydroxylamine
Dapsone hydroxylamine (metabolite) rapidly depletes erythrocyte glutathione levels 𔪠increasing oxidation rate of hemoglobin to methemoglobin⦠G6PD Deficiency
Methemoglobin is unable to bind oxygen 𔪠decreased oxygen delivery to tissues 𔪠cyanosis, dyspnea and tachycardia
Patients at highest risk for dapsone-induced methemoglobinemia include anemic, underlying cardiovascular conditions, chronic respiratory dysfunctions, and elderly patients
Dapsoneās effect may be a dose related. Where elevated dapsone levels occur in renal dysfunction and/or other medications that utilize P-450 cytochrome enzyme pathway
Br J Dermatol. 1993;129(5):507-513.
J Neurooncol (2009) 94:149ā152
Medicine (Baltimore). 2004;83(5):265.Ā
15
PJP Prophylaxis
Infect Dis Clin North Am. 2010;24(1):107-138.
16
Drug-Induced ļæ½Methemoglobinemia
Clinical Presentation and Diagnosis
Clinical Presentation
after exposure to substance that causes MetHb formation
Acute development of hypoxia
dark red, chocolate in color, does not resolve upon oxygenation
Discoloration of the blood
coma, seizures
fatigue, irritability
headache, lightheadedness
Neurologic deterioration
+/- pale, grayish blue colored skin, lips, and nail beds despite normal arterial oxygen pressure (PaO2)
Mild cyanosis
Despite supplemental O2 requirements
Normal arterial oxygen pressure (PaO2)
www.uptodate.com. Methemoglobinemia.
19
Quick Reminder: IPās
MetHb = 21
When to Suspectā¦
Unexplained cyanosis or hypoxia w/ pulse oximetry ~85% (despite supplemental O2)
Prior history of methemoglobinemia
Positive family hx for methemoglobinemia
Positive genetic testing for variant in one of the methemoglobinemia genes
Known exposure to methemoglobinemia-inducing substance
Respiratory or neurologic symptoms (shock if severe)
Dark red or brown blood that does not turn red with oxygenation
http://www.emdocs.net/tox-card-methemoglobinemia/
20
Diagnosis + Work-Up
21
Rule Out Genetic Causes
(include 1st degree relatives)
Initiate Treatment
(if indicated per methemoglobin level and severity of symptoms)
Complete Blood Count (CBC)
(would expect to see normal Hgb 𔪠no compensatory erythrocytosis b/c not enough time to develop)
G6PD Deficiency
(help determine which therapy to use & if pt had dapsone exposure, may see Heinz bodies in blood smear)
Methemoglobin levels > 5%
(to confirm diagnosis & determine if treatment is required)
Eliminate Exposure
(if applicable)
21
Do Use
Do NOT Use
How to Properly Detect Methemoglobin
J Anaesthesiol Clin Pharmacol. 2013;29(1):139
22
Differential Diagnosis
Carbon Monoxide Poisoning
www.uptodate.com. Methemoglobinemia.
23
IPās Levels on 11/2:
MetHb = 21
CarboxyHb = 0.0
Drug-Induced ļæ½Methemoglobinemia
Treatment Options
Treatment Options ā Overview
Initial treatment if MetHb >30% or symptoms other than headache and/or lethargy:
Asymptomatic or mildly symptomatic with MetHb <30% with or without cyanosis
J Med Case Rep. 2012;6:290. Epub 2012 Sep 11
25
1st Line - Treatment Option
Methylene Blue (MB)
FDA Approved IndicationsĀ
Methylene Blue [prescribing information].
26
1st Line - Treatment Option
Methylene Blue (MB)
Pharmacokinetics
J Pharm Sci, 1972, 61(7):1086-90.
27
1st Line - Treatment Option
J Pharm Sci, 1972, 61(7):1086-90.
27
Methylene Blue (MB)
1st Line - Treatment Option
Methylene Blue (MB)
ContraindicationsĀ
Ann Intern Med. 1971;75(1):83
Methylene Blue [prescribing information].
28
1st Line - Treatment Option
Methylene Blue (MB)
Ann Intern Med. 1971;75(1):83
Methylene Blue [prescribing information].
28
1st Line - Treatment Option
Methylene Blue (MB)
Recommended Dosing
Dose Adjustments
West J Med. 1984;140(2):282
Methylene Blue [prescribing information].
29
1st Line - Treatment Option
Methylene Blue (MB)
Monitoring ParametersĀ
Methylene Blue [prescribing information].
30
1st Line - Treatment Option
Methylene Blue (MB)
Expected response
Co-oximetry detects MB as MetHb 𔪠cannot use to follow response of MetHb levels with MB treatment
Ā Br J Clin Pharmacol. 1992;34(3):244-249.
Methylene Blue [prescribing information].
31
1st Line - Treatment Option Alternative
Ascorbic Acid (Vitamin C)
IndicationsĀ
Ascor (ascorbic acid) [prescribing information].
32
1st Line - Treatment Option Alternative
Ascorbic Acid (Vitamin C)
Dosing
Dose Adjustment:
Am J Emerg Med. 2014 Jun;32(6):684.e1-3. Epub 2013 Nov 26.
33
1st Line - Treatment Option Alternative
Ascorbic Acid (Vitamin C)
Expected response
Adverse effects
Monitoring Parameters
Ascor (ascorbic acid) [prescribing information]
34
Other Treatment Options and Recommendations
Cimetidine
Avoidance of Precipitating ExposuresĀ
Genetic Testing
37
Coleman MD, Rhodes LE, Scott AK, et al.
Indian J Crit Care Med. 2014;18(4):253.
35
Summary: Treatment Options ā MOA
Indian J Drugs Dermatol 2018;4:79-81
Toxic Metabolite
36
Drug-Induced ļæ½Methemoglobinemia
Evidence Based Treatment Recommendations
Literature Overview
38
Case Studies
39
Ann Emerg Med. 1990;19(6):677-679
Br J Dermatol. 1995;132(2):257-262.
Tidsskr Nor Laegeforen. 2000;120(13):1549-1551.
Our Patient
IP, a 30-year-old Hispanic female, newly diagnosed with methemoglobinemia secondary to dapsone useā¦
Primary Teamās Assessment and Planā¦
Problem #1
Acute hypoxic respiratory failure 𔪠due to dapsone-induced methemoglobinemia
I agree with not treating methemoglobinemia:
No methylene blue 𔪠G6PD deficiency and MetHb < 30%
No ascorbic acid 𔪠improved after discontinuation of dapsone & no severe symptoms
No cimetidine 𔪠dapsone discontinued to alternative therapy
41
Primary Teamās Assessment and Planā¦
Problem #1
Acute hypoxic respiratory failure 𔪠due to dapsone-induced methemoglobinemia
I agree with not treating methemoglobinemia:
No methylene blue 𔪠G6PD deficiency and MetHb < 30%
No ascorbic acid 𔪠improved after discontinuation of dapsone & no severe symptoms
No cimetidine 𔪠dapsone discontinued to alternative therapy
41
One recommendation I would have made,
would be to consider genetic testing
Primary Teamās Assessment and Planā¦
Problem #2:
Dapsone-induced hemolysis from oxidative stress
42
Primary Teamās Assessment and Planā¦
Problem #3
Acute on chronic anemia of chronic disease (CKD)
I agree:
No G6PD deficiency
Hemolyzed with signs of oxidant stress as seen on peripheral smear w/ bite cells and blister cells
43
Primary Teamās Assessment and Planā¦
Problem #3
Acute on chronic anemia of chronic disease (CKD)
I agree:
Jehovah's witness, refused blood transfusion
Iron stores were repleated and normal
Met restriction criteria, CKD ā no dialysis w/ Hgb < 10 to be initiated on darbepoetin
43
Primary Teamās Assessment and Planā¦
Problem #3
Acute on chronic anemia of chronic disease (CKD)
Unlikely cause of anemia:
If only reason for holding was due to anemia concern, insinuating cause (dapsone) is gone & pt
received ESA
But also, okay to continue holding, with close follow-up outpatient to check Hgb trend and if pt
remained clinically stable
43
Primary Teamās Assessment and Planā¦
Problem #3
Acute on chronic anemia of chronic disease (CKD)
I agree:
No need to keep admitted, oxidant stress hemolysis typically takes 2-3 wks to resolve
43
Primary Teamās Assessment and Planā¦
Problem #4 (and chief complaint upon admission)
Severe diarrhea
44
Patient Update as of 2/21/22:
45
Questions?
Hope Vertrice Askew, PharmD
PGY-1 Pharmacy Resident
Parkland Health
Thank you to the content expert and style advisor:
Dr. Eileen Marley, PharmD, BCOP
Dr. Taylor Epperson, PharmD, BCPS
References
47
Treatment Summary
www.uptodate.com. Methemoglobinemia.
48